Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.37 |
| ▸ | MMP2 | P08253 | 6/20 | 0.35 |
| ▸ | MMP3 | P08254 | 5/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29014239 | 0.86 | GPR84 (0.52) | CPB2GPR84MMP2MMP3MMP1 | |
| SCHEMBL27622663 | 0.84 | GPR84 (0.55) | CPB2GPR84MMP2MMP3MMP1 | |
| SCHEMBL2643540 | 0.84 | GPR84 (0.55) | CPB2GPR84MMP2MMP3MMP1 | |
| SCHEMBL481493 | 0.84 | GPR84 (0.55) | CPB2GPR84MMP2MMP3MMP1 | |
| SCHEMBL8361445 | 0.84 | CPB2 (0.46) | CPB2FOLH1MEN1NPC1KMT2A | |
| SCHEMBL2880166 | 0.84 | CPB2 (0.72) | CPB2FOLH1MEN1NPC1KMT2A | |
| SCHEMBL2706849 | 0.82 | CPB2 (0.44) | CPB2FOLH1MEN1NPC1KMT2A | |
| SCHEMBL27513220 | 0.81 | CPB2 (0.42) | CPB2FOLH1MEN1NPC1KMT2A | |
| SCHEMBL28218803 | 0.80 | HDAC1 (0.48) | CPB2FOLH1MEN1NPC1KMT2A | |
| SCHEMBL2875679 | 0.78 | CPB2 (0.69) | CPB2FOLH1MEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | CPB2 2619/4885FOLH1 2512/4885MEN1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.